ENDRA Life Sciences
NDRA
10 hedge funds and large institutions have $819K invested in ENDRA Life Sciences in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
96% more capital invested
Capital invested by funds: $417K → $819K (+$402K)
25% more funds holding
Funds holding: 8 → 10 (+2)
4.41% more ownership
Funds ownership: 7.68% → 12.1% (+4.4%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$152K |
| 2 |
CFG
Citizens Financial Group
Providence,
Rhode Island
|
+$144K |
| 3 |
ACM
Altium Capital Management
New York
|
+$37.5K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$23K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$295 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$31.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$427 |
| 3 |
CIAM
Caitong International Asset Management
Hong Kong
|
-$19 |
NDRA Hedge Fund Activity: Q2 2026 in Review
10 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q2 2026, worth a combined $819K — up 96% from $417K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NDRA positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $152K. The largest seller was Geode Capital Management, cutting an estimated $31.3K.
- 10 institutional investors held ENDRA Life Sciences (NDRA) as of Q2 2026, up from 8 in Q1 2026.
- Funds reported $819K of ENDRA Life Sciences stock for Q2 2026, up 96% quarter-over-quarter.
- 3 funds opened new ENDRA Life Sciences positions in Q2 2026 and 1 closed out, a net change of +2 holders.
- The largest ENDRA Life Sciences buyer in Q2 2026 was Citadel Advisors, an estimated $152K added.
- The largest ENDRA Life Sciences seller in Q2 2026 was Geode Capital Management, an estimated $31.3K sold.
Based on aggregated 13F filings for Q2 2026.